Oncogenic Role and Potential Regulatory Mechanism of Topoisomerase IIα in a Pan-cancer Analysis

Overview

Journal Sci Rep

Specialty Science

Date 2022 Jul 1

PMID 35778520

Authors

Xiaobo Wang

Jinhua Wang

Li Lyu

Xin Gao

Yinuo Cai

Bo Tang

Affiliations

Soon will be listed here.

Abstract

Topoisomerase IIα (TOP2A) plays an oncogenic role in multiple tumor types. However, no pan-cancer analysis about the function and the upstream molecular mechanism of TOP2A is available. For the first time, we analyzed potential oncogenic roles of TOP2A in 33 cancer types via The Cancer Genome Atlas (TCGA) database. Overexpression of TOP2A was existed in almost all cancer types, and related to poor prognosis and advanced pathological stages in most cases. Besides, the high frequency of TOP2A genetic alterations was observed in several cancer types, and related to prognosis in some cases. Moreover, we conduct upstream miRNAs and lncRNAs of TOP2A to establish ceRNA networks in kidney renal clear cell carcinoma (SNHG3-miR-139-5p), kidney renal papillary cell carcinoma (TMEM147-AS1/N4BP2L2-IT2/THUMPD3-AS1/ERICD/TTN-AS1/SH3BP5-AS1/THRB-IT1/SNHG3/NEAT1-miR-139-5p), liver hepatocellular carcinoma (SNHG3/THUMPD3-AS1/NUTM2B-AS1/NUTM2A-AS1-miR-139-5p and SNHG6/GSEC/SNHG1/SNHG14/LINC00265/MIR3142HG-miR-101-3p) and lung adenocarcinoma (TYMSOS/HELLPAR/SNHG1/GSEC/SNHG6-miR-101-3p). TOP2A expression was generally positively correlated with cancer associated fibroblasts, M0 and M1 macrophages in most cancer types. Furthermore, TOP2A was positively associated with expression of immune checkpoints (CD274, CTLA4, HAVCR2, LAG3, PDCD1 and TIGIT) in most cancer types. Our first TOP2A pan-cancer study contributes to understanding the prognostic roles, immunological roles and potential upstream molecular mechanism of TOP2A in different cancers.

Citing Articles

Targeting TOP2A in Ovarian Cancer: Biological and Clinical Implications.

Borella F, Fucina S, Seminara Y, Denti P, Ferraioli D, Bertero L Curr Oncol. 2024; 31(12):8054-8074.

PMID: 39727717 PMC: 11674396. DOI: 10.3390/curroncol31120594.

mA-Methylated NUTM2B-AS1 Promotes Hepatocellular Carcinoma Stemness Feature via Epigenetically Activating Transcription.

Li W, Zeng M, Ning Y, Lu R, Wei Y, Xu Z J Hepatocell Carcinoma. 2024; 11:2393-2411.

PMID: 39649245 PMC: 11624692. DOI: 10.2147/JHC.S480522.

Comprehensive Analysis of a Six-Gene Signature Predicting Survival and Immune Infiltration of Liposarcoma Patients and Deciphering Its Therapeutic Significance.

Han J, Zhao B, Han X, Sun T, Yue M, Hou M Int J Mol Sci. 2024; 25(14).

PMID: 39063036 PMC: 11277418. DOI: 10.3390/ijms25147792.

Effects of Topoisomerase II alpha Inhibition on Oral Cancer Cell Metabolism and Cancer Stem Cell Function.

Kanagasabai T, Hawaz M, Ellis K, Fah O, Mikhaeil H, Nguyen P Dent Res Oral Health. 2024; 7(2):58-65.

PMID: 38957610 PMC: 11218736. DOI: 10.26502/droh.0076.

Transcriptomic profiling highlights cell proliferation in the progression of experimental pulmonary hypertension in rats.

Luo A, Hao R, Zhou X, Jia Y, Bao C, Yang L Sci Rep. 2024; 14(1):14056.

PMID: 38890390 PMC: 11189536. DOI: 10.1038/s41598-024-64251-w.

References

Porter A, Farr C . Topoisomerase II: untangling its contribution at the centromere. Chromosome Res. 2004; 12(6):569-83. DOI: 10.1023/B:CHRO.0000036608.91085.d1. View

Chen T, Sun Y, Ji P, Kopetz S, Zhang W . Topoisomerase IIα in chromosome instability and personalized cancer therapy. Oncogene. 2014; 34(31):4019-31. PMC: 4404185. DOI: 10.1038/onc.2014.332. View

Zeng S, Liu A, Dai L, Yu X, Zhang Z, Xiong Q . Prognostic value of TOP2A in bladder urothelial carcinoma and potential molecular mechanisms. BMC Cancer. 2019; 19(1):604. PMC: 6582551. DOI: 10.1186/s12885-019-5814-y. View

Xu Y, Zhang F, Li J, Dai J, Liu Q, Tang L . RRM1, TUBB3, TOP2A, CYP19A1, CYP2D6: Difference between mRNA and protein expression in predicting prognosis of breast cancer patients. Oncol Rep. 2015; 34(4):1883-94. DOI: 10.3892/or.2015.4183. View

Zhang R, Xu J, Zhao J, Bai J . Proliferation and invasion of colon cancer cells are suppressed by knockdown of TOP2A. J Cell Biochem. 2018; 119(9):7256-7263. DOI: 10.1002/jcb.26916. View

Wong N, Yeo W, Wong W, Wong N, Chan K, Mo F . TOP2A overexpression in hepatocellular carcinoma correlates with early age onset, shorter patients survival and chemoresistance. Int J Cancer. 2008; 124(3):644-52. DOI: 10.1002/ijc.23968. View

Pei Y, Yin X, Liu X . TOP2A induces malignant character of pancreatic cancer through activating β-catenin signaling pathway. Biochim Biophys Acta Mol Basis Dis. 2017; 1864(1):197-207. DOI: 10.1016/j.bbadis.2017.10.019. View

Du X, Xue Z, Lv J, Wang H . Expression of the Topoisomerase II Alpha (TOP2A) Gene in Lung Adenocarcinoma Cells and the Association with Patient Outcomes. Med Sci Monit. 2020; 26:e929120. PMC: 7774312. DOI: 10.12659/MSM.929120. View

Liu T, Zhang H, Yi S, Gu L, Zhou M . Mutual regulation of MDM4 and TOP2A in cancer cell proliferation. Mol Oncol. 2019; 13(5):1047-1058. PMC: 6487731. DOI: 10.1002/1878-0261.12457. View

10.

Quail D, Joyce J . Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013; 19(11):1423-37. PMC: 3954707. DOI: 10.1038/nm.3394. View

11.

Lei X, Lei Y, Li J, Du W, Li R, Yang J . Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapy. Cancer Lett. 2019; 470:126-133. DOI: 10.1016/j.canlet.2019.11.009. View

12.

Andrews L, Marciscano A, Drake C, Vignali D . LAG3 (CD223) as a cancer immunotherapy target. Immunol Rev. 2017; 276(1):80-96. PMC: 5338468. DOI: 10.1111/imr.12519. View

13.

Das M, Zhu C, Kuchroo V . Tim-3 and its role in regulating anti-tumor immunity. Immunol Rev. 2017; 276(1):97-111. PMC: 5512889. DOI: 10.1111/imr.12520. View

14.

Manieri N, Chiang E, Grogan J . TIGIT: A Key Inhibitor of the Cancer Immunity Cycle. Trends Immunol. 2016; 38(1):20-28. DOI: 10.1016/j.it.2016.10.002. View

15.

Salmena L, Poliseno L, Tay Y, Kats L, Pandolfi P . A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language?. Cell. 2011; 146(3):353-8. PMC: 3235919. DOI: 10.1016/j.cell.2011.07.014. View

16.

Gao X, Li J, Liu Y, Liu Q, Hao L, Liu L . ZNF148 modulates TOP2A expression and cell proliferation via ceRNA regulatory mechanism in colorectal cancer. Medicine (Baltimore). 2017; 96(1):e5845. PMC: 5228706. DOI: 10.1097/MD.0000000000005845. View

17.

Cui Y, Pu R, Ye J, Huang H, Liao D, Yang Y . LncRNA FAM230B Promotes Gastric Cancer Growth and Metastasis by Regulating the miR-27a-5p/TOP2A Axis. Dig Dis Sci. 2020; 66(8):2637-2650. DOI: 10.1007/s10620-020-06581-z. View

18.

Goldman M, Craft B, Hastie M, Repecka K, McDade F, Kamath A . Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol. 2020; 38(6):675-678. PMC: 7386072. DOI: 10.1038/s41587-020-0546-8. View

19.

Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z . GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017; 45(W1):W98-W102. PMC: 5570223. DOI: 10.1093/nar/gkx247. View

20.

Gao J, Aksoy B, Dogrusoz U, Dresdner G, Gross B, Sumer S . Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013; 6(269):pl1. PMC: 4160307. DOI: 10.1126/scisignal.2004088. View